Sanofi Nixes Licensing Deal with Maze Therapeutics Citing FTC Opposition
- December 15, 2023
French drug maker Sanofi is terminating a deal to acquire an exclusive license to Maze Therapeutics Inc.’s experimental treatment for Pompe disease, a potentially fatal genetic disorder that affects the heart and skeletal muscles, after the Federal Trade Commission (FTC) this week moved to block the transaction.
ARTICLE TAGS
You must be logged in to access this content.